Hana Pharm Co., Ltd.
Research Hana Pharm Co., Ltd. (293480.KS) on Bullrun: market cap KRW 147.10B, dividend yield 3.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker293480.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 147.10B
- Dividend yield3.2%
- Financial periodQ2 2026
- RevenueKRW 60.90B
- Net incomeKRW 8.45B
- Free cash flow-KRW 10.68B
- Gross margin60.9%
Valuation Snapshot
latest market cap is KRW 147.10B; dividend yield is 3.2%.
Peer valuation comparison
Latest dividend yield is 3.17% versus a Healthcare sector median of 2.4% (32.1% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 147.10B | n/a | 3.1% | 260 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 260 KRW, yield 3.2%.
About Hana Pharm Co., Ltd.
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.
ETFs that hold Hana Pharm Co., Ltd.
US-listed ETFs
Hana Pharm Co., Ltd. is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hana Pharm Co., Ltd.'s market cap?
Hana Pharm Co., Ltd.'s market capitalization is KRW 147.10B.
Does Hana Pharm Co., Ltd. pay a dividend?
Hana Pharm Co., Ltd. has a dividend yield of 3.2%.
What does Hana Pharm Co., Ltd. do?
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.